A UK epidemiologist and Cochrane Collaboration researcher is suing the drug company Roche in the US, claiming that it defrauded federal and state governments by falsely claiming that its antiviral drug oseltamivir (Tamiflu) could be a powerful tool in mitigating a flu pandemic.
Tom Jefferson, a frequent contributor to The BMJ, is suing as a private whistleblower for $1.5bn (£1.1bn; €1.4bn), roughly the amount that US public health authorities spent building up their pandemic stockpile of oseltamivir. The stockpile is still maintained today, though recent purchases have involved generic versions, as Tamiflu’s main patent expired in 2016.
Should Jefferson win, he would be awarded up to 30% of any monies recovered, while the rest would be returned to public coffers.
Jefferson’s Cochrane acute respiratory infections group was engaged by the UK government to undertake a major review of the effectiveness of oseltamivir in 2009, after …

中文翻译：

---

Cochrane审查员状告罗氏（Roche）称达菲可减缓流感大流行

英国流行病学家和Cochrane合作研究人员正在起诉美国罗氏制药公司，称其欺诈性地声称其抗病毒药物奥司他韦（Tamiflu）可能是缓解流感大流行的有力工具，从而欺骗了联邦和州政府。
汤姆·杰斐逊（Tom Jefferson）是BMJ的经常撰稿人，他以私人举报人的身份起诉，要求赔偿15亿美元（11亿英镑； 14亿欧元），这大约是美国公共卫生部门用于建立大流行的奥司他韦库存的金额。尽管达菲的主要专利于2016年到期，但最近的购买涉及通用版本，直到今天，库存仍保持不变。
如果杰斐逊获胜，他将获得最多30％的追回款项，其余将退还给公共保险箱。
杰斐逊的Cochrane急性呼吸道感染小组由英国政府聘请，在2009年对oseltamivir的有效性进行了一次重大审查。